drug
olaparib
Marketedupdated 3mo agoby AstraZeneca Pharmaceuticals LP
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(1)
Trials studying olaparib
- phase3A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- phase2A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
- phase3Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- phase3Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- phase1Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- phase3Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- phase3Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
- phase1Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 27, 2026
134 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (25)
- Oct 25, 2041method-of-use (U-3931)US 11970530
- Oct 25, 2041method-of-use (U-3931)US 11970530
- Aug 4, 2031method-of-use (U-2480)US 88595625.0y
- Aug 4, 2031method-of-use (U-3333)US 88595625.0y
- Aug 4, 2031method-of-use (U-1634)US 88595625.0y
- Dec 31, 2029formulationUS 84758423.4y
- Dec 31, 2029formulationUS 84758423.4y
- Oct 7, 2029formulationUS 116333963.1y
- Oct 7, 2029formulationUS 116333963.1y
- Oct 7, 2029formulationUS 119750013.1y
- Oct 7, 2029formulationUS 119750013.1y
- Oct 7, 2029formulationUS 120486953.1y
- Oct 7, 2029formulationUS 120486953.1y
- Oct 7, 2029formulationUS 121448103.1y
- Oct 7, 2029formulationUS 121448103.1y
- Oct 7, 2029formulationUS 121788163.1y
- Oct 7, 2029formulationUS 121788163.1y
- Sep 24, 2028compositionUS 82474162.1y
- Sep 8, 2027compositionUS 74494641.1y
- Sep 8, 2027compositionUS 74494641.1y
- Aug 12, 2027method-of-use (U-2822)US 8071579362d
- Aug 12, 2027method-of-use (U-3333)US 8071579362d
- Aug 12, 2027method-of-use (U-1634)US 8143241362d
- Aug 12, 2027method-of-use (U-3333)US 8143241362d
- Aug 12, 2027method-of-use (U-3333)US 8143241362d
FDA exclusivities (6)
- May 8, 2027ODE-306Orphan Drug (7y)266d
- May 8, 2027ODE-306Orphan Drug (7y)266d
- Dec 27, 2026ODE-283Orphan Drug (7y)134d
- Dec 27, 2026ODE-283Orphan Drug (7y)134d
- May 31, 2026I-914Indication (3y)
- May 31, 2026I-914Indication (3y)
News(2)
- ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everIf AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.biospace · 11d ago
- Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsWith a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.biospace · 23d ago
Data sources
last refreshed 33m ago
Found something off?
comments(0)
5-min edit window · permanent after that